GeneDx Holdings Corp. (WGS)

NASDAQ: WGS · Real-Time Price · USD
57.34
-5.93 (-9.37%)
At close: May 7, 2025, 4:00 PM
56.10
-1.24 (-2.16%)
After-hours: May 7, 2025, 5:26 PM EDT
-9.37%
Market Cap 1.64B
Revenue (ttm) 330.14M
Net Income (ttm) -38.58M
Shares Out 28.53M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE 46.15
Dividend n/a
Ex-Dividend Date n/a
Volume 2,257,175
Open 64.10
Previous Close 63.27
Day's Range 56.30 - 64.10
52-Week Range 18.80 - 117.75
Beta 2.04
Analysts Strong Buy
Price Target 81.60 (+42.31%)
Earnings Date Apr 30, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is headquartered in Stamford, Connecticut. [Read more]

Sector Healthcare
Founded 2017
Employees 1,000
Stock Exchange NASDAQ
Ticker Symbol WGS
Full Company Profile

Financial Performance

In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $81.6, which is an increase of 42.31% from the latest price.

Price Target
$81.6
(42.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

GeneDx Announces Completion of Fabric Genomics Acquisition

GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretati...

11 hours ago - Business Wire

GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript

GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2025 Earnings Conference Call April 30, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - Chief Executive Officer Kev...

7 days ago - Seeking Alpha

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2025.

7 days ago - Business Wire

GeneDx: Strengthening Leadership In Genomic Diagnostics

GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings. GeneDx will report Q1 2025 earnings o...

9 days ago - Seeking Alpha

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation.

21 days ago - Business Wire

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025.

4 weeks ago - Business Wire

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the commercial expansion into Inborn Errors of Immunity (IEI).

4 weeks ago - Business Wire

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced inducement grants under Nasdaq Listing Rule 5635(c)(4).

6 weeks ago - Business Wire

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025.

7 weeks ago - Business Wire

GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at th...

7 weeks ago - Business Wire

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support ...

7 weeks ago - Business Wire

GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich

GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash, which makes me hesitant. At 7x sales, WGS stock feels expensive, given its current financials. If GeneDx can pr...

2 months ago - Seeking Alpha

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing.

2 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study.

2 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reduci...

2 months ago - Seeking Alpha

GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge

Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.

2 months ago - CNBC Television

GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript

GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...

2 months ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 months ago - Accesswire

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

2 months ago - Business Wire